Skip to main content

Table 1 Demographic data of the complete study cohort for the main experiments (PiB– vs PiB+)

From: Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition

  Group (total, n = 353)  
Basic characteristic PiB– (n = 253) PiB+ (n = 100) P valuea
Global PiB deposition, mean ± SEM 1.11 ± 0.004 1.91 ± 0.038 <0.001
Clinical diagnosis, N/M/D 187/50/16 28/29/43 <0.001
Gender, male/female 95/158 38/62 >0.05
Age (years), mean ± SEM 69.94 ± 0.5 73.00 ± 0.7 <0.001
CDR, mean ± SEM 0.15 ± 0.02 0.5 ± 0.04 <0.001
MMSE z score,b mean ± SEM –0.13 ± 0.07 –1.91 ± 0.20 <0.001
Education, mean ± SEM 10.65 ± 0.3 10.82 ± 0.5 >0.05
ApoE4-positive, n/N (%) 39/253 (15%) 57/100 (57%) <0.001
  1. Details of clinical diagnosis and pathological states (CDR score, MMSE z score, and global PiB deposition (SUVR)) of each subject are shown in Additional file 3
  2. PiB Pittsburgh-compound B, SUVR standardized uptake value ratio, – or + PiB-PET positivity, MMSE Mini-Mental State Examination, CDR Clinical Dementia Rating, ApoE apolipoprotein E, SEM standard error of mean, n number of subjects, N/M/D cognitively normal/mild impairment/dementia
  3. a P value, significance by unpaired t-test except for clinical diagnosis, gender, and ApoE
  4. bA revised value of the MMSE score with consideration for age, gender, and education level
  5. Pearson’s chi-square test